Project Grant R21AI199783
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $788,453 under Project Grant R01AI198560 on September 2, 2026, to identify essential Plasmodium falciparum determinants of erythrocyte invasion using genome-scale functional genomic approaches. The research will employ a novel transposon-based strategy to map critical genes and molecular pathways underlying red blood cell invasion across multiple P. falciparum strains with distinct phenotypes in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Pennsylvania State University $196,625 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct single-cell transcriptomics research on sexual dimorphism during Plasmodium falciparum gametocytogenesis. The research applies single-cell RNA sequencing to uncover the molecular mechanisms governing sexual development and differentiation in the malaria parasite. The study...
- The National Institute of Allergy and Infectious Diseases awarded $436,750 to the University of Georgia Research Foundation on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct cellular and molecular profiling of artemisinin-induced persister phenotypes in Plasmodium falciparum. The research addresses the emergence of artemisinin resistance in malaria parasites and focuses on understanding how the parasites enter a dormant ring stage when exposed...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- The National Institute of Allergy and Infectious Diseases awarded Iowa State University $578,956 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of axoneme assembly during Plasmodium falciparum gametogenesis, a study aimed at advancing malaria vaccine development. The project, designated R01AI195769, runs through June 30, 2031, with work performed in Ames, Iowa. The research addresses the mechanisms of flagellar...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $203,060 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the ecology and transmission dynamics of Plasmodium malariae in Cameroon. The research will assess the spatial distribution and seasonal trends of P. malariae in Bangolan, a lakeshore area in Cameroon's northwest region, through molecular surveillance conducted via repeated...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $426,938 effective August 1, 2025 through July 31, 2027 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on evaluating combined inhibition strategies against Plasmodium falciparum merozoite invasion into erythrocytes, a critical target for antimalarial drug development. The project will assess the...
- The National Institute of Allergy and Infectious Diseases awarded The Pennsylvania State University $247,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study mechanisms of translational repression release in Plasmodium parasites during transmission from mammals to mosquito vectors. The research applies reverse genetic, transcriptomic, proteomic, and microscopy-based approaches to determine how malaria parasites control gene expression before and...
- The National Institute of Allergy and Infectious Diseases awarded the National Science And Technology Development Agency $117,504 on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct biochemical investigations of two Plasmodium falciparum folate transporters, PFFT1 and PFFT2, to characterize their function and substrate scope. The work will assess the transporters' ability to transport antifolate drugs, identify...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
The National Institute of Allergy and Infectious Diseases awarded the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. $223,728 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Plasmodium falciparum gametocyte differentiation and adhesion mechanisms as part of Project Grant R21AI199783. The funded research addresses malaria transmission by examining the sexual stage parasites (gametocytes) responsible for mosquito-borne spread. Current first-line antimalarial treatments do not effectively eliminate these sexual stages, allowing continued transmission for over a week post-treatment. The project seeks to identify and characterize genes expressed in sexual stages that are predicted to be exported to red blood cells, with preliminary work showing that disruption of two candidate genes resulted in loss of gametocytogenesis and morphological changes. The research aims to support the development of alternative malaria-blocking strategies to address safety limitations of existing anti-gametocytocidal drugs like primaquine and tafenoquine in mass drug administration programs in endemic regions. Performance runs through August 31, 2028, with work based in Bethesda, Maryland. The funding is a project grant, an assistance type supporting competitive research proposals with defined performance periods.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $223.7k | 8/28/26 |